ERBB2 and neoplasm: The selection of i.t. injection was informed by an earlier imaging and biodistribution study that showed that i.v. injected HER2-targeted AuNPs labeled with 111In exhibited very low tumour uptake at 48 h post-injection (p.i.)[1.2 percent injected dose/g (%ID/g)] and high uptake in the spleen (19.2% ID/g), liver (2.7% ID/g) and kidneys (2.3% ID/g) (Chattopadhyay et al. 2012) (Fig. 3).